About Euticals
Euticals is a company based in Milano (Italy) founded in 1984 was acquired by Curia in May 2016. Euticals has completed 1 acquisition, including Archimica. Euticals offers products and services including Cytarabine, Hydroxyurea, Mianserin, and Sucralfate. Euticals operates in a competitive market with competitors including Laurus Labs, Symbiotec, Provepharm Life Solutions, Beijing Biostar Technologies and SeQuent, among others.
- Headquarter Milano, Italy
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Archimica S.P.A.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Euticals
Euticals offers a comprehensive portfolio of products and services, including Cytarabine, Hydroxyurea, Mianserin, and Sucralfate.
Nucleoside analogue for cancer treatment applications
Modified urea used in oncology medications
Tetracyclic compound for psychiatric treatments
Saccharose sulfate for gastrointestinal therapies
Funding Insights of Euticals
Investors in Euticals
Euticals has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Curia, Clessidra Private Equity and Private Equity Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Clessidra Private Equity is focused on mid-cap company investments.
|
Locked | Locked | Locked | |
|
Private Equity Partners is engaged in private equity and venture capital investments.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Euticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Euticals
Euticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Archimica.
Investment portfolio details for Euticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Develops nucleic acid analysis tools for research and clinical diagnostics applications
|
Locked | Locked | 1999 | Locked |
Complete acquisition details for Euticals
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Euticals
Detailed financials for Euticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Euticals Comparisons
Peer comparison for Euticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Euticals
Euticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Laurus Labs, Symbiotec, Provepharm Life Solutions, Beijing Biostar Technologies and SeQuent, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical and biotechnology company
|
|
| Locked | Locked | Locked |
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
|
|
| Locked | Locked | Locked |
APIs and drug products are developed and valorized in pharmaceuticals.
|
|
| Locked | Locked | Locked |
APIs, intermediates, and biochemical reagents are developed and manufactured.
|
|
| Locked | Locked | Locked |
APIs are developed and manufactured for therapeutic areas.
|
|
| Locked | Locked | Locked |
Contract development, manufacturing, and analytical services for APIs are offered.
|
Detailed competitors of Euticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Euticals
Complete news archive for Euticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Euticals
Euticals was founded in 1984 and raised its 1st funding round 27 years after it was founded.
Euticals is headquartered in Milano, Italy.
Margalit Fine is the current CEO of Euticals.
Euticals was founded in 1984 and is based in Milano, Italy, with operations in the pharmaceutical sector. Plants are located in Italy, France, Germany, and the USA. A portfolio of over 200 API products is maintained, covering areas such as anti-inflammatory, anticancer, anti-infective, cardiovascular, and CNS therapies. Eighteen fine chemical products are also offered. The company was acquired by Albany Molecular Research on May 5, 2016.
Euticals's top competitors include Laurus Labs, Symbiotec and NGL Fine Chem.
Euticals offers Cytarabine, Hydroxyurea, Mianserin, and Sucralfate.
Euticals has made 1 acquisition, including Archimica.
Euticals has 4 investors. Key investors include Curia, Clessidra Private Equity, Private Equity Partners, and Mandarin Capital Partners.